Related Experiment Videos
Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study
T Saida1, K Tashiro, Y Itoyama
1Department of Neurology, Utano National Hospital, Kyoto, Japan. saida@unh.hosp.go.jp
Neurology
|February 25, 2005
Summary
Interferon beta-1b (IFNB-1b) at 250 mcg significantly reduced relapse rates in Japanese patients with relapsing-remitting multiple sclerosis (RRMS). This finding suggests shared disease characteristics and genetic factors between Japanese and white patients with MS.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) research has predominantly focused on Caucasian populations.
- Japanese patients with MS exhibit distinct clinical presentations, including optic-spinal MS (OS-MS) and classic MS (C-MS), with less frequent chronic progressive forms.
- Understanding IFNB-1b efficacy in diverse ethnic groups is crucial for personalized treatment strategies.
Purpose of the Study:
- To evaluate the effectiveness of interferon beta-1b (IFNB-1b) in Japanese individuals diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- To compare the efficacy of two different dosages of IFNB-1b (50 mcg and 250 mcg) in this patient cohort.
- To explore potential differences in treatment response between OS-MS and C-MS subtypes.
Main Methods:
- A randomized trial involving 205 Japanese RRMS patients receiving either 50 mcg or 250 mcg of IFNB-1b subcutaneously every other day for up to two years.
- Primary efficacy endpoint was the annual relapse rate; secondary endpoints included MRI lesion changes and disability/neurological scales.
- Subgroup analyses were conducted for OS-MS and C-MS patient groups.
Main Results:
- The 250 mcg IFNB-1b group demonstrated a statistically significant 28.6% reduction in annual relapse rate compared to the 50 mcg group (p=0.047).
- All secondary efficacy measures favored the higher 250 mcg dosage.
- Subgroup analyses indicated similar treatment effects in OS-MS and C-MS patients, though not statistically significant due to limited sample sizes.
Conclusions:
- A dosage of 250 mcg of IFNB-1b was effective in significantly reducing relapse rates and MRI lesion progression in Japanese RRMS patients.
- The study suggests comparable efficacy of IFNB-1b in both optic-spinal MS and classic MS subtypes within the Japanese population.
- The observed treatment response implies shared underlying pathogenesis and genetic factors in MS across Japanese and Caucasian populations.